These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17338244)

  • 1. [Immunotherapy of invasive cancer of the urinary bladder].
    Kharchenko VP; Kaprin AD; Ivanov SA; Klimenko AA
    Vopr Onkol; 2006; 52(6):659-62. PubMed ID: 17338244
    [No Abstract]   [Full Text] [Related]  

  • 2. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular research in cancer: future clinical applications.
    Ratliff TL
    Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
    Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
    Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy of bladder carcinoma].
    Damianov Kh; Koleva P; Patrashkov T
    Khirurgiia (Sofiia); 1987; 40(6):35-41. PubMed ID: 3325689
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune function determination in patients with bladder cancer.
    Brosman SA; Fahey JL
    Natl Cancer Inst Monogr; 1978 Dec; (49):321-3. PubMed ID: 311893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bladder cancer; staging and treatment].
    Essed E; Boon ME; Donker PJ
    Ned Tijdschr Geneeskd; 1980 May; 124(20):786-92. PubMed ID: 6155618
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathological variants of invasive bladder cancer according to their suggested clinical significance.
    Lopez-Beltran A; Requena MJ; Cheng L; Montironi R
    BJU Int; 2008 Feb; 101(3):275-81. PubMed ID: 17986288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunologic and clinical parameters in patients with bladder cancer].
    Sagaster P; Flamn J; Misksche M
    Wien Med Wochenschr; 1977 May; 127(10):315-9. PubMed ID: 327705
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
    Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
    Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
    deVere White RW; Katz MH; Steinberg GD
    J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines.
    Videira PA; Calais FM; Correia M; Ligeiro D; Crespo HJ; Calais F; Trindade H
    Urology; 2009 Oct; 74(4):944-50. PubMed ID: 19428084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could PD-L1 prove to be an effective therapeutic target for bladder cancer?
    Hafez N; Petrylak DP
    Immunotherapy; 2015; 7(1):1-2. PubMed ID: 25572474
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
    Margel D; Tal R; Baniel J
    J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.